Nan Anjan, Ghandehari Hamidreza, Hebert Carla, Siavash Hessam, Nikitakis Nikolaos, Reynolds Mark, Sauk John J
Department of Pharmaceutical Sciences, University of Maryland, Baltimore, MD, 21201, USA.
J Drug Target. 2005 Apr;13(3):189-97. doi: 10.1080/10611860500065187.
Human squamous cell carcinoma of the head and neck (SCCHN) is characterized by over expression of a tumor cell surface-specific receptor namely Hsp47/CBP2 that makes it a favorable candidate for targeted delivery of anticancer drugs. Several synthetic peptides have been identified as effective ligands for binding to CBP2. The purpose of this study is to investigate the potential of water-soluble N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-doxorubicin (Dox) conjugates containing a Hsp47/CBP2 binding peptide sequence, namely WHYPWFQNWAMA for targeted delivery to SCCHN. An HPMA copolymer containing Dox and CBP2 targeting peptide conjugated via lysosomally degradable glycylphenylalanylleucylglycine (GFLG) spacer was synthesized by free radical precipitation copolymerization. A control polymer without targeting moiety was also synthesized. The conjugates were characterized for drug content, peptide content, molecular weight and molecular weight distribution. The uptake of polymeric conjugates by both drug resistant and drug sensitive SCCHN cells were determined in vitro by flow cytometry using FACS scan analysis. Cytotoxicity of the conjugates towards drug sensitive as well as multidrug resistant SCCHN cells were evaluated by a clonal survival assay and compared to free Dox. The cytotoxicity of the free peptide was similarly evaluated. The internalization and subcellular fate of the conjugates in drug sensitive SCCHN cells was monitored using confocal microscopy. The new targetable copolymer contained 0.16 mmole peptide/g polymer. Studies on drug sensitive SCCHN cells demonstrated lesser uptake of both targeted and non-targeted conjugates compared to free Dox suggesting a slower endocytic mechanism of uptake for the conjugates as opposed to rapid diffusion of free Dox. At higher Dox equivalent concentrations (>20 microM) the targeted conjugate showed significantly higher uptake (p < or = 0.028) than the non-targeted conjugate. The uptake of the targeted conjugate was inhibited in the presence of an anti Hsp47 antibody suggesting the involvement of active receptor mediated endocytosis in cell entry of the conjugate. Compared to free Dox, the targeted and non-targeted conjugates caused marginally lower inhibition (p < or = 0.01) of the drug sensitive SCCHN cells. In contrast, the same conjugates showed significantly higher uptake (p < or = 0.004) by drug resistant SCCHN cells and caused significantly higher inhibition (p < or = 0.02) of drug resistant SCCHN cells when compared to free Dox. Results suggest that the polymeric conjugates were able to overcome drug resistance. Confocal microscopy studies demonstrated the uptake of the polymeric conjugates, followed by internalization, intralysosomal localization and subsequent release of Dox. HPMA copolymer-Dox-peptide conjugates targeted to SCCHN cells were able to overcome drug resistance and increase efficacy in vitro. The results suggest that targetable polymeric conjugates have potential to improve systemic head and neck cancer chemotherapy by increasing tumor localization and reducing dose-limiting toxicity.
人类头颈部鳞状细胞癌(SCCHN)的特征是肿瘤细胞表面特异性受体Hsp47/CBP2的过度表达,这使其成为抗癌药物靶向递送的理想候选者。几种合成肽已被鉴定为与CBP2结合的有效配体。本研究的目的是研究含有Hsp47/CBP2结合肽序列(即WHYPWFQNWAMA)的水溶性N-(2-羟丙基)甲基丙烯酰胺(HPMA)共聚物-阿霉素(Dox)缀合物靶向递送至SCCHN的潜力。通过自由基沉淀共聚合成了一种含有通过溶酶体可降解的甘氨酰苯丙氨酰亮氨酰甘氨酸(GFLG)间隔基缀合的Dox和CBP2靶向肽的HPMA共聚物。还合成了一种没有靶向部分的对照聚合物。对缀合物进行了药物含量、肽含量、分子量和分子量分布的表征。通过使用FACS扫描分析的流式细胞术在体外测定耐药和药敏SCCHN细胞对聚合物缀合物的摄取。通过克隆存活试验评估缀合物对药敏以及多药耐药SCCHN细胞的细胞毒性,并与游离Dox进行比较。同样评估了游离肽的细胞毒性。使用共聚焦显微镜监测缀合物在药敏SCCHN细胞中的内化和亚细胞命运。新的可靶向共聚物含有0.16毫摩尔肽/克聚合物。对药敏SCCHN细胞的研究表明,与游离Dox相比,靶向和非靶向缀合物的摄取均较少,这表明缀合物的内吞摄取机制较慢,而游离Dox则是快速扩散。在较高的Dox等效浓度(>20 microM)下,靶向缀合物的摄取显著高于非靶向缀合物(p≤0.028)。在抗Hsp47抗体存在下,靶向缀合物的摄取受到抑制,表明活性受体介导的内吞作用参与了缀合物进入细胞的过程。与游离Dox相比,靶向和非靶向缀合物对药敏SCCHN细胞的抑制作用略低(p≤0.01)。相比之下,与游离Dox相比,相同的缀合物在多药耐药SCCHN细胞中的摄取显著更高(p≤0.004),并且对多药耐药SCCHN细胞的抑制作用显著更高(p≤0.02)。结果表明,聚合物缀合物能够克服耐药性。共聚焦显微镜研究表明聚合物缀合物被摄取,随后内化、溶酶体内定位以及随后Dox的释放。靶向SCCHN细胞的HPMA共聚物-Dox-肽缀合物能够克服耐药性并提高体外疗效。结果表明,可靶向的聚合物缀合物有可能通过增加肿瘤定位和降低剂量限制毒性来改善全身性头颈部癌化疗。